UGN-102 yields 80% complete response at 3 months in recurrent LG-IR-NMIBC
New treatment shows promise for recurrent low-grade bladder cancer
This single-arm phase 3 trial evaluated 6 weekly intravesical instillations of UGN-102 in 240 patients with recurrent low-grade intermediate…
A new treatment called UGN-102 helped 80% of patients with recurrent bladder cancer achieve a complete response within three months.
Intravesical gemcitabine and docetaxel provide effective treatment for high-risk non-muscle-invasive bladder cancer
Sequential gemcitabine and docetaxel show promise for bladder cancer
This systematic review and meta-analysis of 883 patients evaluated the efficacy and safety of intravesical sequential gemcitabine and doceta…
A new treatment combination involving two drugs may offer an effective way to manage high-risk bladder cancer while remaining well tolerated…